Plan Overview

A Data Management Plan created using DMPTool

Title: Suppression of duplication-mediated genome rearrangements by protein sumoylation

Creator: Huilin Zhou

Affiliation: University of California, San Diego (ucsd.edu)

Funder: National Institutes of Health (nih.gov)

Funding opportunity number: PA-20-185

Grant: GM116897

Template: NIH-Default DMSP

Project abstract:

Genome rearrangements are mutations that cause numerous genetic diseases including cancer, immune deficiencies, and developmental disorders. Genome rearrangements are caused by defects in DNA replication and repair pathways, as well as the presence of numerous "at-risk" sequences in the human genome that are prone to mutations. Protein sumoylation is reversible and involves the opposing actions of two families of enzymes; the E3 ligases that catalyze the attachment of Small Ubiquitin-like MOdifier (SUMO) to substrates, and the SUMO specific proteases that remove them. Using the yeast Saccharomyces cerevisiae as a model organism, our prior studies have established a major role of these enzymes in preventing genome rearrangements and showed that site-specific sumoylation of the Mini-Chromosome Maintenance (MCM) complex plays a hitherto unknown role in regulating its loading at DNA replication origins. Remarkably, defects in this control cause impaired DNA replication, resulting in a drastic accumulation of gross chromosomal rearrangements (GCRs). Because inherited mutations of the SUMO pathway genes cause genome instability syndromes in mammals, our study will impact human health for two major reasons: 1) a comprehensive understanding of the genetic
consequences that arise from mutations to the SUMO pathways, with regards to DNA replication, will impact the development of assays for cancer diagnosis. 2) Identifying the mechanism by which SUMO regulates DNA replication will lead to new therapeutic interventions of human diseases. Our proposed studies will pursue three specific aims. First, we will perform genetic analysis of the MCM subunits to examine their roles in maintaining cell growth and suppressing GCRs. Second, we will investigate the function of MCM sumoylation during DNA replication, focusing on its role in MCM loading and formation of the replicative DNA helicase. Third, we will perform biochemical reconstitutions of SUMO dependent MCM loading to understand its mechanisms, using cell-free assays that we have developed. Altogether, the goal is to understand how SUMO modification regulates MCM loading and how cells utilize this new pathway to prevent genome rearrangements.

**Start date:** 03-31-2024

**End date:** 03-30-2028

**Last modified:** 05-30-2023

**Copyright information:**

The above plan creator(s) have agreed that others may use as much of the text of this plan as they would like in their own plans, and customize it as necessary. You do not need to credit the creator(s) as the source of the language used, but using any of the plan's text does not imply that the creator(s) endorse, or have any relationship to, your project or proposal.
Suppression of duplication-mediated genome rearrangements by protein sumoylation

**Data Type**

*Types and amount of scientific data expected to be generated in the project: Summarize the types and estimated amount of scientific data expected to be generated in the project.*

Describe data in general terms that address the type and amount/size of scientific data expected to be collected and used in the project (e.g., 256-channel EEG data and fMRI images from ~50 research participants). Descriptions may indicate the data modality (e.g., imaging, genomic, mobile, survey), level of aggregation (e.g., individual, aggregated, summarized), and/or the degree of data processing that has occurred (i.e., how raw or processed the data will be).

In this proposed project, data will be generated via the following methods: real-time quantitative polymerase chain reaction (PCR), and mass spectrometry (MS). This data will be collected from a minimum of 3 independent experiments, with each independent experiment consisting of 3 groups. The total size of the data collected is projected to be 100 GB.

Specifically, we expect to generate MS data about peptide sequencing and quantification. The raw MS data are analyzed by open source softwares commonly used in the proteomics community, including TPP and Mascot. We expect to submit both the raw MS data and processed data, which include protein identity and quantification, to public repositories once the research is published. Real-time PCR data are analyzed by Excel.

**Scientific data that will be preserved and shared, and the rationale for doing so: Describe which scientific data from the project will be preserved and shared and provide the rationale for this decision.**

In this proposed project, the cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data. Final files used to generate specific analyses to answer the Specific Aims and related results will also be shared. The rationale for sharing only cleaned data is to foster ease of data reuse. All our published data are preserved and shared with the research community via publishers. Our raw and processed proteomics data will be submitted to public repositories with identifier reported in our published work.
Metadata, other relevant data, and associated documentation: Briefly list the metadata, other relevant data, and any associated documentation (e.g., study protocols and data collection instruments) that will be made accessible to facilitate interpretation of the scientific data.

We do not expect to generate any Metadata in our work.

Related Tools, Software and/or Code

State whether specialized tools, software, and/or code are needed to access or manipulate shared scientific data, and if so, provide the name(s) of the needed tool(s) and software and specify how they can be accessed.

Our proteomics data are analyzed by open source softwares including TPP and Mascot, which are public available. All other softwares used in our work are accessible via subscription fees. For instance, we pay annual subscription to access Lasergene to analyze our DNA sequencing data. All softwares used in our study are described in our published work.

We do not expect to generate any imaging data.

Standards

State what common data standards will be applied to the scientific data and associated metadata to enable interoperability of datasets and resources, and provide the name(s) of the data standards that will be applied and describe how these data standards will be applied to the scientific data generated by the research proposed in this project. If applicable, indicate that no consensus standards exist

In accordance with FAIR Principles for data, we will use open file formats (e.g. JPEG, PDF, HTML, etc.) and persistent unique identifiers (PIDs) such as RRIDs for resources (e.g., organisms, plasmids, antibodies, software tools, and databases). We calculate standard deviation and obtain calibration curve for multiple measurements to evaluate the significance of our measurements, including quantitative PCR and quantitative MS results. The statistic findings (p-value, etc.) are reported in our published results.
Data Preservation, Access, and Associated Timelines

Repository where scientific data and metadata will be archived: Provide the name of the repository(ies) where scientific data and metadata arising from the project will be archived; see Selecting a Data Repository.

Our data will be made available immediately following the publication of our work through journals and public repositories in case MS data is used for publication, which will be described in the method section of our work.

How scientific data will be findable and identifiable: Describe how the scientific data will be findable and identifiable, i.e., via a persistent unique identifier or other standard indexing tools.

Repository used in our study will provide identifiers for our proteomics dataset, which will be described in the method section of our published work. Data will be discoverable online through standard web search. The other data will be available from the journals and papers that we publish.

When and how long the scientific data will be made available: Describe when the scientific data will be made available to other users (i.e., no later than time of an associated publication or end of the performance period, whichever comes first) and for how long data will be available.

All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.

Access, Distribution, or Reuse Considerations

Factors affecting subsequent access, distribution, or reuse of scientific data: NIH expects that in drafting Plans, researchers maximize the appropriate sharing of scientific data. Describe and justify any applicable factors or data use limitations affecting subsequent access, distribution, or reuse of scientific data related to informed consent, privacy and confidentiality protections, and any other considerations that may limit the extent of data sharing. See Frequently Asked Questions for examples of justifiable reasons for limiting sharing of data.

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific data generated by the proposal.
Whether access to scientific data will be controlled: State whether access to the scientific data will be controlled (i.e., made available by a data repository only after approval).

Controlled access will not be used. The data that is shared will be shared by unrestricted download.

Protections for privacy, rights, and confidentiality of human research participants:
If generating scientific data derived from humans, describe how the privacy, rights, and confidentiality of human research participants will be protected (e.g., through de-identification, Certificates of Confidentiality, and other protective measures).

Not applicable to our study.

Oversight of Data Management and Sharing

Describe how compliance with this Plan will be monitored and managed, frequency of oversight, and by whom at your institution (e.g., titles, roles).

Lead PI __Huilin Zhou__, ORCID: _0000-0002-1350-4430_, will be responsible for the day-to-day oversight of lab/team data management activities and data sharing. Broader issues of DMS Plan compliance oversight and reporting will be handled by the PI and Co-I team as part of general [campus(es)] stewardship, reporting, and compliance processes.